{"id":7393,"date":"2020-01-23T16:54:25","date_gmt":"2020-01-23T11:24:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7393"},"modified":"2021-07-24T12:57:45","modified_gmt":"2021-07-24T07:27:45","slug":"recent-pharma-happenings-for-kintai-horizon-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics","title":{"rendered":"Tepezza receives approval; a new way to treat Alzheimer\u2019s"},"content":{"rendered":"\n

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye<\/strong><\/h3>\n\n\n\n

Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye<\/a> is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under Priority Review and had received Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.<\/p>\n\n\n\n

Thyroid eye is a rare disease; however, up to 50 per cent of patients with Graves\u2019 disease, the most common autoimmune disorder, are at the risk of developing TED. <\/p>\n\n\n\n

Tepezza is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). It is administered once every three weeks for a total of eight infusions. The clinical trials Phase II and III showed improvements in patients as early as six weeks, as well as continued improvement across the entire 24-week course of treatment. <\/p>\n\n\n\n

Research conducted at Temple University shows a possible novel way to tackle the onset of Alzheimer\u2019s disease<\/a><\/strong><\/h3>\n\n\n\n

The study, undertaken at the Lewis Katz School of Medicine at Temple, points towards the use of pharmacological chaperones, small drug molecules, to get rid of clumps of dysfunctional proteins. The study revealed a new approach to hamper the process of damaging the neurons in the brain by restoring the levels of VPS35, a sorting molecule, that eliminates the clump of old proteins.<\/p>\n\n\n\n

They can offer a new approach to deal with neurological conditions, as they are relatively inexpensive. Moreover, the drugs do not block an enzyme or a receptor but target a cellular mechanism, reducing the risk of significant side effects.<\/p>\n\n\n\n

Kintai Therapeutics, a Flagship Pioneering company, has announced the progress of KTX-0200, a novel oral anti-obesity agent, into IND-enabling studies<\/strong><\/h3>\n\n\n\n

Treatment with KTX-0200 has helped with sustained weight loss of 14% in chronic diet-induced obesity rodent models. Moreover, it also helped in improving markers of health such as glucose tolerance and insulin sensitivity. <\/p>\n\n\n\n

The drug, KTX-0200, an oral small molecule anti-obesity agent, has demonstrated the potential cure of treating diabetes. Moreover, it might help in improving liver health<\/a>. <\/p>\n\n\n\n

The new research would help curb the increasing burden of obesity, and other metabolic diseases, including type 2 diabetes, NASH, and cardiovascular diseases. <\/p>\n","protected":false},"excerpt":{"rendered":"

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision. The drug was approved under Priority Review and had received Orphan Drug, Fast […]<\/p>\n","protected":false},"author":1,"featured_media":7394,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17629,17975,17072,17973,17974,349,1469,639,5789,17971,17972,2023],"industry":[17225],"therapeutic_areas":[17242,17240,17227,17245],"class_list":["post-7393","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-cardiovascular-diseases","tag-horizon-therapeutics","tag-kintai-therapeutics","tag-ktx-0200","tag-latest-pharma-news","tag-nash","tag-pharma-news","tag-recent-pharma-news","tag-tepezza","tag-thyroid-eye","tag-type-2-diabetes","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nFDA nod to Tepezza; Kintai's KTX-0200; Latest in Alzheimer's Research<\/title>\n<meta name=\"description\" content=\"Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA nod to Tepezza; Kintai's KTX-0200; Latest in Alzheimer's Research\" \/>\n<meta property=\"og:description\" content=\"Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-23T11:24:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"853\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA nod to Tepezza; Kintai's KTX-0200; Latest in Alzheimer's Research","description":"Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics","og_locale":"en_US","og_type":"article","og_title":"FDA nod to Tepezza; Kintai's KTX-0200; Latest in Alzheimer's Research","og_description":"Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-23T11:24:25+00:00","article_modified_time":"2021-07-24T07:27:45+00:00","og_image":[{"width":853,"height":533,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics","name":"FDA nod to Tepezza; Kintai's KTX-0200; Latest in Alzheimer's Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020.jpg","datePublished":"2020-01-23T11:24:25+00:00","dateModified":"2021-07-24T07:27:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Tepezza (teprotumumab-trbw) is the first-ever treatment approved for thyroid eye is a progressive autoimmune disorder hampering the ability of vision.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-kintai-horizon-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020.jpg","width":853,"height":533,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/23164039\/pharma_news_23.01.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiovascular Diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Horizon Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kintai Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">KTX-0200<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tepezza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Thyroid Eye<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 diabetes<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease<\/span>","<span class=\"advgb-post-tax-term\">Cardiovascular Diseases<\/span>","<span class=\"advgb-post-tax-term\">Horizon Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Kintai Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">KTX-0200<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Tepezza<\/span>","<span class=\"advgb-post-tax-term\">Thyroid Eye<\/span>","<span class=\"advgb-post-tax-term\">Type 2 diabetes<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 23, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 23, 2020 4:54 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7393"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7393\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7394"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7393"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7393"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}